@entity3446 -eluting stent implantation in ST-elevation acute XXXX : a clinical and angiographic study.

@entity1 @entity1455 @entity6 @entity75 @entity256 @entity3446 @entity1188 @entity299 @entity583 @entity204 @entity715
BACKGROUND: @entity3446 -eluting stents (SES) have recently been proven to reduce restenosis and reintervention compared with bare stents. Safety and effectiveness of SES in acute @entity583 remain unknown. METHODS AND RESULTS: Since April 16, 2002, a policy of routine SES implantation has been instituted in our hospital, with no clinical or anatomic restrictions, as part of the RESEARCH ( @entity3446 -Eluting Stent Evaluated At Rotterdam Cardiology Hospital) registry. During 6 months of enrollment, 96 @entity1 with ST-elevation acute @entity583 underwent percutaneous recanalization and SES implantation; these @entity1 comprise the study population. The incidence of major adverse @entity299 ( @entity204 , nonfatal @entity583 , reintervention) was evaluated. Six-month angiographic follow-up was scheduled per protocol. At baseline, @entity6 was present in 12.5% and multivessel disease in 46.9%. Primary angioplasty was performed in 89 @entity1 (92.7%). @entity1188 location was anterior in 41 (42.7%) of the cases, and 12 @entity1 (12.5%) had @entity1455 . Postprocedural TIMI-3 flow was achieved in 93.3% of the cases. In-hospital mortality was 6.2%. One @entity1 (1.1%) had reinfarction and @entity75 reintervention the first day as a result of distal dissection and acute vessel occlusion. During follow-up (mean follow-up of 218+/-75 days), 1 @entity1 died (1.1%), no @entity1 had recurrent @entity583 , and there were no additional reinterventions. No early or late stent @entity715 were documented. At angiographic follow-up (70%), late loss was -0.04+/-0.25, and no @entity1 presented @entity256 . CONCLUSIONS: In this study, @entity3446 -eluting stent implantation for @entity1 with ST-elevation acute @entity583 was safe without documented @entity256 at 6 months.
